Reduced postprandial bone resorption and greater rise in GLP-1 in overweight and obese individuals after an α-glucosidase inhibitor: a double-blinded randomized crossover trial
- 11 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 32 (7), 1379-1386
- https://doi.org/10.1007/s00198-020-05791-5
Abstract
Summary When taken with a meal, α-glucosidase inhibitors (α-GI) reduce the rise in postprandial glucose and increase glucagon-like peptide-1 (GLP-1), and this may lower bone turnover. In this study, a salacinol-type α-GI increased GLP-1 and markedly reduced postprandial bone resorption compared to placebo, suggesting it could have implications for bone health. Introduction Animal and clinical trials indicate that α-glucosidase inhibitors attenuate postprandial glycemic indices and increase secretion of GLP-1. In addition, GLP-1 acts on bone by inhibiting resorption. The goal in this study was to determine if a salacinol α-GI alters postprandial bone turnover and can be explained by changes in serum GLP-1. Methods In this double-blind, placebo-controlled crossover study, healthy overweight/obese adults (body mass index 29.0 ± 3.8 kg/m2; 21–59 years; n = 21) received a fixed breakfast and, in random order, were administered Salacia chinensis (SC; 500 mg) or placebo. A fasting blood sample was taken before and at regular intervals for 3 h after the meal. Serum was measured for bone turnover markers, C-terminal telopeptide of type I collagen (CTX) and osteocalcin, and for glycemic indices and gut peptides. Results Compared to placebo, SC attenuated the bone resorption marker, CTX, at 60, 90, and 120 min (p < 0.05) after the meal, and decreased osteocalcin, at 180 min (p < 0.05). As expected, SC attenuated the postprandial rise in glucose compared with placebo, whereas GLP-1 was increased at 60 min (p < 0.05) with SC. Serum GLP-1 explained 41% of the variance for change in postprandial CTX (p < 0.05). Conclusion This study indicates that attenuating postprandial glycemic indices, with an α-GI, markedly decreases postprandial bone resorption and can be explained by the rise in GLP-1. Future studies should determine whether longer term α-GI use benefits bone health.Keywords
Funding Information
- National Institute of Food and Agriculture (NJAES - 0153866)
- OmniActive Health Technologies
This publication has 46 references indexed in Scilit:
- Consumption of nutrients and insulin resistance suppress markers of bone turnover in subjects with abdominal obesityBone, 2020
- High Fat Mixed Meal Tolerance Test Leads to Suppression of Osteocalcin Decrease in Obese Insulin Resistant Subjects Compared to Healthy AdultsNutrients, 2018
- Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variabilityOsteoporosis International, 2017
- Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2016
- Feeding and Bone Turnover in Gastric BypassJournal of Clinical Endocrinology & Metabolism, 2014
- Comparison of the Hypoglycemic Effect of Acarbose Monotherapy in Patients With Type 2 Diabetes Mellitus Consuming an Eastern or Western Diet: A Systematic Meta-analysisClinical Therapeutics, 2013
- Bone Metabolism in Obesity and Weight LossAnnual Review of Nutrition, 2012
- Feeding and boneArchives of Biochemistry and Biophysics, 2010
- Biology of Incretins: GLP-1 and GIPGastroenterology, 2007
- Effect of feeding on bone turnover markers and its impact on biological variability of measurementsBone, 2002